Ignite Creation Date:
2025-12-24 @ 9:18 PM
Ignite Modification Date:
2025-12-30 @ 4:11 PM
Study NCT ID:
NCT03781804
Status:
COMPLETED
Last Update Posted:
2024-05-29
First Post:
2018-12-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2023-07-07', 'type': 'ACTUAL'}}}}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'John.Messina@optinose.com', 'phone': '267-521-0565', 'title': 'John Messina, PharmD, SVP of Clinical Research & Medical Affairs', 'organization': 'OptiNose'}, 'certainAgreement': {'restrictionType': 'GT60', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Pretreatment (Screening/Run-in) period to end of treatment (Week 24)', 'eventGroups': [{'id': 'EG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID', 'otherNumAtRisk': 111, 'deathsNumAtRisk': 111, 'otherNumAffected': 37, 'seriousNumAtRisk': 111, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID', 'otherNumAtRisk': 109, 'deathsNumAtRisk': 109, 'otherNumAffected': 37, 'seriousNumAtRisk': 109, 'deathsNumAffected': 0, 'seriousNumAffected': 2}, {'id': 'EG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID', 'otherNumAtRisk': 112, 'deathsNumAtRisk': 112, 'otherNumAffected': 14, 'seriousNumAtRisk': 112, 'deathsNumAffected': 0, 'seriousNumAffected': 3}], 'otherEvents': [{'term': 'Epistaxis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 109, 'numAffected': 13}, {'groupId': 'EG002', 'numAtRisk': 112, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'Asthma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 109, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 112, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 109, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 112, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 112, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'Cataract nuclear', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 109, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 112, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'Cataract cortical', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 109, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 112, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 109, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 112, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'Acute sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 109, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 112, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 112, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 112, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}], 'seriousEvents': [{'term': 'Alcoholic pancreatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 112, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 112, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'COVID-19 pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 112, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'Pneumonia staphylococcal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 112, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'Ankle fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 112, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'Uterine leiomyoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 112, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'Adenomyosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 112, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'Ovarian cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 109, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 112, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}], 'frequencyThreshold': '2'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior and/or Posterior) at the End of Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '108', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '108', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.58', 'spread': '0.161', 'groupId': 'OG000'}, {'value': '-1.60', 'spread': '0.163', 'groupId': 'OG001'}, {'value': '-0.62', 'spread': '0.161', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '4 Weeks', 'description': 'Change from baseline to the end of Week 4 in average total instantaneous AM scores (evaluation of symptom severity immediately preceding the time of scoring) for each symptom: nasal congestion, nasal discharge (anterior and/or posterior), facial pain/pressure sensation. Baseline scores are the averaged total instantaneous AM scores over the last 7 days of the single blind run in period, and the end of Week 4, scores are averaged over the 7 days from the subject diary. Range of scores for each nasal symptom is 0= none, 1 = mild, 2 = moderate, 3 = severe. Composite score is a sum of the 3 symptom scores and will range from 0 to 9.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'PRIMARY', 'title': 'Change From Baseline to Week 24/Early Termination (ET) in the Average Percent of the Volume Opacified in the Ethmoid and Maxillary Sinuses', 'denoms': [{'units': 'Participants', 'counts': [{'value': '98', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '-5.58', 'spread': '1.436', 'groupId': 'OG000'}, {'value': '-6.20', 'spread': '1.412', 'groupId': 'OG001'}, {'value': '-1.60', 'spread': '1.421', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 24', 'description': 'Change from baseline to Week 24/ET in the average percent of ethmoid and maxillary sinus volume opacified as measured by CT. Percent volume opacified can range from 0% to 100%. Outcome measure is the percentage change from percent opacification at baseline to percent opacification at Week 24; therefore, change in opacification volume can range from -100% to 100%. For example, if Baseline opacification was 68.22% and Week 24 opacification was 66.11%, then the change would be reported as -2.11%.', 'unitOfMeasure': 'Percentage of volume opacified', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Defined Timepoint - Subject Symptoms and Functioning as Measured by the Sinonasal Outcome Test - 22-item (SNOT-22) Total Score and Sub Domains', 'denoms': [{'units': 'Participants', 'counts': [{'value': '98', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '93', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '-18.05', 'spread': '1.687', 'groupId': 'OG000'}, {'value': '-22.77', 'spread': '1.709', 'groupId': 'OG001'}, {'value': '-10.16', 'spread': '1.723', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 24', 'description': 'The SNOT-22 is a subject-completed questionnaire that consists of 22 symptoms and social/emotional consequences of their nasal disorder across several domains including: rhinologic, ear/facial pain, psychological dysfunction, and sleep dysfunction. Total scores range from 0-110. Each item is rated as follows: 0=no problem, 1=very mild problem, 2=mild or slight problem,3=moderate problem, 4=severe problem, 5=problem as bad as it can be.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior and/or Posterior)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '96', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.89', 'spread': '0.204', 'groupId': 'OG000'}, {'value': '-2.18', 'spread': '0.208', 'groupId': 'OG001'}, {'value': '-1.35', 'spread': '0.208', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 12', 'description': 'Change from baseline in average total instantaneous AM scores (evaluation of symptom severity immediately preceding the time of scoring) for each symptom: nasal congestion, nasal discharge (anterior and/or posterior), facial pain/pressure sensation. Baseline scores are the averaged total instantaneous AM scores over the last 7 days of the single blind run in period, and the end of Week 4, scores are averaged over the 7 days from the subject diary. Range of scores for each nasal symptom is 0= none, 1 = mild, 2 = moderate, 3 = severe. Composite score is a sum of the 3 symptom scores and will range from 0 to 9.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Nasal Congestion Measured by AM and PM Diary Symptom Scores', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '96', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'AM Diary Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '96', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.71', 'spread': '0.074', 'groupId': 'OG000'}, {'value': '-0.84', 'spread': '0.076', 'groupId': 'OG001'}, {'value': '-0.45', 'spread': '0.076', 'groupId': 'OG002'}]}]}, {'title': 'PM Diary Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '96', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.68', 'spread': '0.075', 'groupId': 'OG000'}, {'value': '-0.82', 'spread': '0.076', 'groupId': 'OG001'}, {'value': '-0.41', 'spread': '0.076', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '12 Weeks', 'description': 'Subjects will report both instantaneous (evaluation of symptom severity immediately preceding the time of scoring) and reflective (evaluation of symptom severity over the past 12 hours), The Nasal Symptom Scale scores as 0=none, 1=mild-symptoms clearly present but minimal awareness, and easily tolerated, 2= moderate - definite awareness of symptoms that is bothersome but tolerable, 3 = severe - symptoms that are hard to tolerate, cause interference with activities or daily living.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change in Sense of Smell Scores Measured by AM and PM Diary Symptom Scores', 'denoms': [{'units': 'Participants', 'counts': [{'value': '110', 'groupId': 'OG000'}, {'value': '107', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'AM Diary Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '96', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.60', 'spread': '0.078', 'groupId': 'OG000'}, {'value': '-0.54', 'spread': '0.079', 'groupId': 'OG001'}, {'value': '-0.31', 'spread': '0.079', 'groupId': 'OG002'}]}]}, {'title': 'PM Diary Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '96', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.54', 'spread': '0.078', 'groupId': 'OG000'}, {'value': '-0.56', 'spread': '0.080', 'groupId': 'OG001'}, {'value': '-0.32', 'spread': '0.079', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '12 Weeks', 'description': 'Subjects will report both instantaneous (evaluation of symptom severity immediately preceding the time of scoring) and reflective (evaluation of symptom severity over the past 12 hours) The sense of smell scored as 0= normal, 1=slightly impaired, 2=moderately impaired, 3=absent. The change reported in the results is calculated by subtracting the score reported at Baseline from the score reported at Visit 4 (Week 12).', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Nasal Discharge (Anterior and/or Posterior) Measured by AM and PM Diary Symptom Scores', 'denoms': [{'units': 'Participants', 'counts': [{'value': '110', 'groupId': 'OG000'}, {'value': '107', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'AM Diary Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '96', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.65', 'spread': '0.075', 'groupId': 'OG000'}, {'value': '-0.74', 'spread': '0.076', 'groupId': 'OG001'}, {'value': '-0.43', 'spread': '0.077', 'groupId': 'OG002'}]}]}, {'title': 'PM Diary Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '96', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.58', 'spread': '0.077', 'groupId': 'OG000'}, {'value': '-0.72', 'spread': '0.078', 'groupId': 'OG001'}, {'value': '-0.37', 'spread': '0.078', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '12 Weeks', 'description': 'Subjects will report both instantaneous (evaluation of symptom severity immediately preceding the time of scoring) and reflective (evaluation of symptom severity over the past 12 hours). The Nasal Symptom Scale scores as 0=none, 1=mild-symptoms clearly present but minimal awareness, and easily tolerated, 2= moderate - definite awareness of symptoms that is bothersome but tolerable, 3 = severe - symptoms that are hard to tolerate, cause interference with activities or daily living.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change in Facial Pain or Pressure Sensation Measured by AM and PM Diary Symptom Scores', 'denoms': [{'units': 'Participants', 'counts': [{'value': '110', 'groupId': 'OG000'}, {'value': '107', 'groupId': 'OG001'}, {'value': '110', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'AM Diary Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '96', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.53', 'spread': '0.078', 'groupId': 'OG000'}, {'value': '-0.61', 'spread': '0.079', 'groupId': 'OG001'}, {'value': '-0.48', 'spread': '0.079', 'groupId': 'OG002'}]}]}, {'title': 'PM Diary Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '96', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.52', 'spread': '0.077', 'groupId': 'OG000'}, {'value': '-0.57', 'spread': '0.079', 'groupId': 'OG001'}, {'value': '-0.43', 'spread': '0.078', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '12 Weeks', 'description': 'Subjects will report both instantaneous (evaluation of symptom severity immediately preceding the time of scoring) and reflective (evaluation of symptom severity over the past 12 hours). The Nasal Symptom Scale scores as 0=none, 1=mild-symptoms clearly present but minimal awareness, and easily tolerated, 2= moderate - definite awareness of symptoms that is bothersome but tolerable, 3 = severe - symptoms that are hard to tolerate, cause interference with activities or daily living.\n\nThe value reported in the results is calculated by subtracting the score reported by the patient at Baseline from the score reported by the patient at Visit 4 (Week 12).', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Week 24/Early Termination (ET) in the Average Percent of the Volume Opacified in the Ethmoid and Maxillary Sinuses Among Patient Populations', 'denoms': [{'units': 'Participants', 'counts': [{'value': '98', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'Nasal Polyps Present', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '62', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-6.01', 'spread': '1.741', 'groupId': 'OG000'}, {'value': '-4.64', 'spread': '1.744', 'groupId': 'OG001'}, {'value': '1.29', 'spread': '1.727', 'groupId': 'OG002'}]}]}, {'title': 'Nasal Polyps Absent', 'denoms': [{'units': 'Participants', 'counts': [{'value': '35', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.52', 'spread': '2.389', 'groupId': 'OG000'}, {'value': '-7.90', 'spread': '2.287', 'groupId': 'OG001'}, {'value': '-5.50', 'spread': '2.309', 'groupId': 'OG002'}]}]}, {'title': 'Prior Sinus Surgery', 'denoms': [{'units': 'Participants', 'counts': [{'value': '45', 'groupId': 'OG000'}, {'value': '40', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-7.58', 'spread': '2.156', 'groupId': 'OG000'}, {'value': '-8.91', 'spread': '2.235', 'groupId': 'OG001'}, {'value': '-1.65', 'spread': '2.185', 'groupId': 'OG002'}]}]}, {'title': 'No Prior Sinus Surgery', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '58', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.30', 'spread': '1.913', 'groupId': 'OG000'}, {'value': '-3.82', 'spread': '1.787', 'groupId': 'OG001'}, {'value': '-0.95', 'spread': '1.810', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '24 Weeks', 'description': 'Change from baseline to Week 24/ET in the average percent of ethmoid and maxillary sinus volume opacified as measured by CT for CRS with Nasal Polyps (NP) and without NP sub-groups and in patients with and without previous sinus surgery. Percent volume opacified can range from 0% to 100%. Outcome measure is percentage change from percent opacification at baseline to percent opacification at Week 24; therefor, change in opacification volume can range from -100% to 100%. For example, if Baseline opacification was 68.22% and Week 24 opacification was 66.11%, then the change would be reported as -2.11%.', 'unitOfMeasure': 'percentage of volume opacified', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Week 24/ET in the Lund-Mackay Staging System Total Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.40', 'spread': '0.269', 'groupId': 'OG000'}, {'value': '-0.46', 'spread': '0.267', 'groupId': 'OG001'}, {'value': '0.10', 'spread': '0.266', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 24', 'description': 'Lund-Mackay Staging System: Lund-Mackay (LM) system (Lund and Mackay, 1993) assigns to each of 10 sinus cavities (left and right maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal) a score of 0 (no opacification), 1 (partial opacification), or 2 (total opacification), plus a 0-2 score for each of the left and right ostiomeatal complex (OMC). The total LM score for a CT scan ranges from 0-24.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Week24/ET in the Lund-Mackay Staging System Total Scores for Ethmoids and Maxillary Sinuses Combined', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '0.12', 'spread': '0.148', 'groupId': 'OG000'}, {'value': '0.04', 'spread': '0.149', 'groupId': 'OG001'}, {'value': '0.37', 'spread': '0.148', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '24 Weeks', 'description': 'Lund-Mackay Staging System: Lund-Mackay (LM) system (Lund and Mackay, 1993) assigns to each of 10 sinus cavities (left and right maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal) a score of 0 (no opacification), 1 (partial opacification), or 2 (total opacification), plus a 0-2 score for the ostiomeatal complex (OMC).\n\nThe values reported for this outcome are the change in total opacification of the left and right maxillary and ethmoid sinuses (Visit 6 \\[Wk 24\\] score minus Baseline score). Each visit score can range from a total of 0-12 (sum of 0-2 score assigned for each of left and right maxillary, left and right anterior ethmoid, and left and right posterior ethmoid).', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Week24/ET in the Lund-Mackay Staging System Total Scores for Sinus Pairs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'Ethmoid Sinus Anterior', 'categories': [{'measurements': [{'value': '0.06', 'spread': '0.064', 'groupId': 'OG000'}, {'value': '-0.01', 'spread': '0.063', 'groupId': 'OG001'}, {'value': '0.07', 'spread': '0.064', 'groupId': 'OG002'}]}]}, {'title': 'Ethmoid Sinus Posterior', 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.066', 'groupId': 'OG000'}, {'value': '-0.04', 'spread': '0.067', 'groupId': 'OG001'}, {'value': '0.15', 'spread': '0.068', 'groupId': 'OG002'}]}]}, {'title': 'Maxillary Sinus', 'categories': [{'measurements': [{'value': '0.04', 'spread': '0.049', 'groupId': 'OG000'}, {'value': '0.09', 'spread': '0.051', 'groupId': 'OG001'}, {'value': '0.12', 'spread': '0.052', 'groupId': 'OG002'}]}]}, {'title': 'Frontal Sinus', 'categories': [{'measurements': [{'value': '0.08', 'spread': '0.072', 'groupId': 'OG000'}, {'value': '0.01', 'spread': '0.071', 'groupId': 'OG001'}, {'value': '0.01', 'spread': '0.070', 'groupId': 'OG002'}]}]}, {'title': 'Sphenoid Sinus', 'categories': [{'measurements': [{'value': '0.04', 'spread': '0.067', 'groupId': 'OG000'}, {'value': '-0.03', 'spread': '0.068', 'groupId': 'OG001'}, {'value': '0.08', 'spread': '0.069', 'groupId': 'OG002'}]}]}, {'title': 'Ostiomeatal Complex', 'categories': [{'measurements': [{'value': '-0.66', 'spread': '0.129', 'groupId': 'OG000'}, {'value': '-0.47', 'spread': '0.129', 'groupId': 'OG001'}, {'value': '-0.31', 'spread': '0.129', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 24', 'description': 'Lund-Mackay Staging System: Lund-Mackay (LM) system (Lund and Mackay, 1993) assigns to each of 10 sinus cavities (left and right maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal) a score of 0 (no opacification), 1 (partial opacification), or 2 (total opacification), plus a 0-2 score for the ostiomeatal complex (OMC).\n\nEach sinus pair (left and right side) listed below can achieve a total score of 0-4 (sum of 0-2 for each side). The values reported below are calculated by subtracting the total score at Baseline from the total score at Visit 6 (Wk 24).', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Week 24/ET in Average Percent of Sinus Volume Occupied by Disease in the Worst Maxillary Sinus as Measured by CT Scan Assessment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '98', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '-14.70', 'spread': '2.23', 'groupId': 'OG000'}, {'value': '-12.62', 'spread': '2.3', 'groupId': 'OG001'}, {'value': '-7.61', 'spread': '2.29', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 24', 'unitOfMeasure': 'Percent opacified volume', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Week 24/ET in Average Percent of Sinus Volume Occupied by Disease in the Worst Ethmoid Sinus as Measured by CT Scan Assessment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '98', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '-7.31', 'spread': '1.43', 'groupId': 'OG000'}, {'value': '-7.43', 'spread': '1.44', 'groupId': 'OG001'}, {'value': '-3.76', 'spread': '1.44', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 24', 'unitOfMeasure': 'Percent opacified volume', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Week 24/ET in Average Percent of Sinus Volume Occupied by Disease in the Worst Sinus Between the Maxillary and Ethmoid Sinuses as Measured by CT Scan Assessment Among Patient Populations', 'denoms': [{'units': 'Participants', 'counts': [{'value': '98', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'Full Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '98', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-11.27', 'spread': '1.81', 'groupId': 'OG000'}, {'value': '-10.39', 'spread': '1.83', 'groupId': 'OG001'}, {'value': '-6.51', 'spread': '1.82', 'groupId': 'OG002'}]}]}, {'title': 'CRSwNP SubGroup', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '62', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-6.54', 'spread': '1.77', 'groupId': 'OG000'}, {'value': '-6.72', 'spread': '1.81', 'groupId': 'OG001'}, {'value': '-3.23', 'spread': '1.79', 'groupId': 'OG002'}]}]}, {'title': 'CRSsNP SubGroup', 'denoms': [{'units': 'Participants', 'counts': [{'value': '35', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-7.88', 'spread': '2.37', 'groupId': 'OG000'}, {'value': '-7.89', 'spread': '2.37', 'groupId': 'OG001'}, {'value': '-3.88', 'spread': '2.34', 'groupId': 'OG002'}]}]}, {'title': 'Subjects with Prior Sinus Surgery', 'denoms': [{'units': 'Participants', 'counts': [{'value': '45', 'groupId': 'OG000'}, {'value': '40', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-11.29', 'spread': '2.67', 'groupId': 'OG000'}, {'value': '-12.44', 'spread': '2.89', 'groupId': 'OG001'}, {'value': '-3.24', 'spread': '2.85', 'groupId': 'OG002'}]}]}, {'title': 'Subjects without Prior Sinus Surgery', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '58', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-11.00', 'spread': '2.46', 'groupId': 'OG000'}, {'value': '-8.83', 'spread': '2.30', 'groupId': 'OG001'}, {'value': '-8.39', 'spread': '2.33', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '24 Weeks', 'description': 'Percent of sinus volume occupied by disease in the worst sinus between maxillary and ethmoid sinuses for the total population, chronic rhinosinusitis with nasal polyps (CRSwNP) subgroup, chronic rhinosinusitis without nasal polyps (CRSsNP) subgroup, patients with previous sinus surgery subgroup, and without previous surgery subgroup.', 'unitOfMeasure': 'Percent opacified volume', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Data is provided for the total population and 4 subgroups. The population of the subgroups will not equal the total population, as they are only a portion of subjects from the total.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Week 24/ET in the Zeinrich Modification of Lund-Mackay Staging System Total Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.98', 'spread': '0.65', 'groupId': 'OG000'}, {'value': '-1.95', 'spread': '0.64', 'groupId': 'OG001'}, {'value': '-0.03', 'spread': '0.65', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 24', 'description': 'Zeinrich Modification of the Lund-Mackay Staging System:\n\nZeinrich modified the LM system by creating subdivisions within "partial opacification" and increasing the range of scores to 0-5 based on percent opacification: 0 = 0%, 1 = 1%-25%, 2 = 26%-50%, 3 = 51%-75%, 4 = 76%- 99%, and 5 = 100% for each sinus. Total score ranges from 0 to 50.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Week 24/ET in the Zeinrich Modification of Lund-Mackay Staging System for Ethmoids and Maxillary Sinuses Combined', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.21', 'spread': '0.43', 'groupId': 'OG000'}, {'value': '-1.44', 'spread': '0.43', 'groupId': 'OG001'}, {'value': '-0.19', 'spread': '0.42', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 24', 'description': 'Zeinrich Modification of the Lund-Mackay Staging System:\n\nZeinrich modified the LM system by creating subdivisions within "partial opacification" and increasing the range of scores to 0-5 based on percent opacification: 0 = 0%, 1 = 1%-25%, 2 = 26%-50%, 3 = 51%-75%, 4 = 76%- 99%, and 5 = 100% The total score for the combined ethmoids and maxillary sinuses can range from 0-30 (0-5 for each left and right of the anterior ethmoid, posterior ethmoid, and maxillary sinuses). The outcome values presented in the results are determined by subtracting the total score at Baseline from the total score at Week 24.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Week 24/ET in the Zeinrich Modification of Lund-Mackay Staging System for the Sinus Pairs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'Anterior Ethmoid Sinus Pair', 'categories': [{'measurements': [{'value': '-0.39', 'spread': '0.17', 'groupId': 'OG000'}, {'value': '-0.53', 'spread': '0.17', 'groupId': 'OG001'}, {'value': '-0.19', 'spread': '0.17', 'groupId': 'OG002'}]}]}, {'title': 'Posterior Ethmoid Sinus Pair', 'categories': [{'measurements': [{'value': '-0.33', 'spread': '0.18', 'groupId': 'OG000'}, {'value': '-0.55', 'spread': '0.18', 'groupId': 'OG001'}, {'value': '0.03', 'spread': '0.18', 'groupId': 'OG002'}]}]}, {'title': 'Maxillary Sinus Pair', 'categories': [{'measurements': [{'value': '-0.53', 'spread': '0.18', 'groupId': 'OG000'}, {'value': '-0.39', 'spread': '0.17', 'groupId': 'OG001'}, {'value': '-0.08', 'spread': '0.17', 'groupId': 'OG002'}]}]}, {'title': 'Frontal Sinus Pair', 'categories': [{'measurements': [{'value': '0.12', 'spread': '0.20', 'groupId': 'OG000'}, {'value': '-0.16', 'spread': '0.20', 'groupId': 'OG001'}, {'value': '0.05', 'spread': '0.20', 'groupId': 'OG002'}]}]}, {'title': 'Sphenoid Sinus Pair', 'categories': [{'measurements': [{'value': '0.15', 'spread': '0.20', 'groupId': 'OG000'}, {'value': '-0.16', 'spread': '0.19', 'groupId': 'OG001'}, {'value': '0.20', 'spread': '0.19', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 24', 'description': 'Zeinrich Modification of the Lund-Mackay Staging System:\n\nZeinrich modified the LM system by creating subdivisions within "partial opacification" and increasing the range of scores to 0-5 based on percent opacification: 0 = 0%, 1 = 1%-25%, 2 = 26%-50%, 3 = 51%-75%, 4 = 76%- 99%, and 5 = 100% Each sinus pair (left and right side) listed below can achieve a total score of 0-10 (sum of score on each side). The values reported for this outcome calculated by subtracting the score at Baseline from the score at Visit 6 (Wk 24).', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Week 24/ET in the Zeinrich Modification of Lund-Mackay Staging System for the Worst Sinus Between Maxillary and Ethmoid Sinuses Among Patient Populations', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'Total Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '99', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.59', 'spread': '0.11', 'groupId': 'OG000'}, {'value': '-0.60', 'spread': '0.11', 'groupId': 'OG001'}, {'value': '-0.45', 'spread': '0.11', 'groupId': 'OG002'}]}]}, {'title': 'CRSwNP', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '62', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.49', 'spread': '0.13', 'groupId': 'OG000'}, {'value': '-0.57', 'spread': '0.14', 'groupId': 'OG001'}, {'value': '-0.30', 'spread': '0.14', 'groupId': 'OG002'}]}]}, {'title': 'CRSsNP', 'denoms': [{'units': 'Participants', 'counts': [{'value': '36', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.70', 'spread': '0.18', 'groupId': 'OG000'}, {'value': '-0.61', 'spread': '0.18', 'groupId': 'OG001'}, {'value': '-0.64', 'spread': '0.18', 'groupId': 'OG002'}]}]}, {'title': 'Subjects with Prior Sinus Surgery', 'denoms': [{'units': 'Participants', 'counts': [{'value': '45', 'groupId': 'OG000'}, {'value': '40', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.48', 'spread': '0.16', 'groupId': 'OG000'}, {'value': '-0.78', 'spread': '0.17', 'groupId': 'OG001'}, {'value': '-0.33', 'spread': '0.17', 'groupId': 'OG002'}]}]}, {'title': 'Subjects without Prior Sinus Surgery', 'denoms': [{'units': 'Participants', 'counts': [{'value': '54', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '58', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.70', 'spread': '0.15', 'groupId': 'OG000'}, {'value': '-0.51', 'spread': '0.14', 'groupId': 'OG001'}, {'value': '-0.54', 'spread': '0.14', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 24', 'description': 'Zeinrich Modification of the Lund-Mackay Staging System:\n\nZeinrich modified the LM system by creating subdivisions within "partial opacification" and increasing the range of scores to 0-5 based on percent opacification: 0 = 0%, 1 = 1%-25%, 2 = 26%-50%, 3 = 51%-75%, 4 = 76%- 99%, and 5 = 100%', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Data provided for full population and CRSwNP, CRSsNP, subjects with prior sinus surgery, and subjects without prior sinus surgery subgroups. Number of participants analyzed in the subgroups will be less than the total overall, as these are only portions of the total population.'}, {'type': 'SECONDARY', 'title': 'Time Comparison to First Acute Exacerbation of Chronic Sinusitis', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '21', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '23.44', 'spread': '0.55', 'groupId': 'OG000'}, {'value': '17.19', 'spread': '0.25', 'groupId': 'OG001'}, {'value': '19.73', 'spread': '0.69', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': '24 Weeks', 'description': 'Comparing the distribution of time to first acute exacerbation of chronic sinusitis, defined as a worsening of symptoms that requires escalation of treatment', 'unitOfMeasure': 'Weeks', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Number of patients experiencing exacerbation within each treatment group.'}, {'type': 'SECONDARY', 'title': 'Percentage of Subjects Requiring Rescue Medication After Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'timeFrame': '8 Weeks', 'description': 'Recording of each dose of approved rescue medication after the Week 4 visit through Week 12', 'reportingStatus': 'POSTED', 'populationDescription': 'We were unable to complete this analysis due to a misunderstanding on the part of the subjects in the definition of "rescue medication". It was confirmed across most countries and sites that subjects indicated use of rescue medication mistakenly, thinking they were being asked to report whether they took the study medication. This data could not be fully reconciled and, therefore, no analysis was completed.'}, {'type': 'SECONDARY', 'title': 'Change in Sleep Quality as Measured by the Pittsburgh Sleep Quality Index (PSQI)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '98', 'groupId': 'OG001'}, {'value': '96', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '97', 'groupId': 'OG000'}, {'value': '98', 'groupId': 'OG001'}, {'value': '96', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.66', 'spread': '0.291', 'groupId': 'OG000'}, {'value': '-1.48', 'spread': '0.291', 'groupId': 'OG001'}, {'value': '-0.91', 'spread': '0.294', 'groupId': 'OG002'}]}]}, {'title': 'Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '97', 'groupId': 'OG001'}, {'value': '92', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.12', 'spread': '0.292', 'groupId': 'OG000'}, {'value': '-1.77', 'spread': '0.294', 'groupId': 'OG001'}, {'value': '-1.09', 'spread': '0.301', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '12 Weeks, 24 Weeks', 'description': 'The PSQI is a validated, self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate 7 "component" scores (each ranging between 0 and 3): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these 7 components yields 1 global score ranging between 0 and 21. Higher values represent a worse outcome.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set. Population sizes differ based on number of patients that completed the assessment at each timepoint.'}, {'type': 'SECONDARY', 'title': 'Change in Overall Health From Baseline to Week 4 and Week 24/ET as Measured by the Percent of Subjects Improved as Indicated by the Patient Global Impression of Change (PGIC)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '109', 'groupId': 'OG000'}, {'value': '103', 'groupId': 'OG001'}, {'value': '104', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '109', 'groupId': 'OG000'}, {'value': '103', 'groupId': 'OG001'}, {'value': '104', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '84', 'groupId': 'OG000'}, {'value': '77', 'groupId': 'OG001'}, {'value': '57', 'groupId': 'OG002'}]}]}, {'title': 'Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '98', 'groupId': 'OG001'}, {'value': '94', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '78', 'groupId': 'OG000'}, {'value': '80', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Week 4, Week 24', 'description': 'Global impression of change will be assessed using a subject-completed PGIC scale range: 1 - Very much improved, 2 - Much improved, 3 - Minimally improved, 4 - No change, 5 - Minimally worse, 6 - Much worse, 7 - Very much worse', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Population size at each timepoint differs based on the number of patients that completed the assessment at the timepoint.'}, {'type': 'SECONDARY', 'title': 'Severity of Depression at Week 24 as Measured by the Quick Inventory of Depression Symptomatology (QIDS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '102', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.24', 'spread': '0.31', 'groupId': 'OG000'}, {'value': '-0.80', 'spread': '0.31', 'groupId': 'OG001'}, {'value': '-0.62', 'spread': '0.31', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 24', 'description': 'The 16-item QIDS (Rush et al. 2003) is designed to assess the severity of depressive symptoms. The QIDS is available in a self-rated version and assesses all the criterion symptom domains designated by the American Psychiatry Association Diagnostic and Statistical Manual of Mental Disorders - 5th edition to diagnose a major depressive episode. The 7-day period prior to assessment is the usual time frame for assessing symptom severity. Scores range from 0 to 27, where higher scores indicate a worse outcome.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change in the 36-Item Short Form Health Survey Version 2 (SF-36v2) Mental Composite Score (MCS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '101', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '101', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.1', 'spread': '0.810', 'groupId': 'OG000'}, {'value': '1.65', 'spread': '0.820', 'groupId': 'OG001'}, {'value': '1.41', 'spread': '0.834', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '24 Weeks', 'description': 'Change from baseline to Week 24/ET on the MCS of the 36-Item Short Form Health Survey version 2 (SF-36v2). The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire. The scale range is from 0-100. A lower score means more disability and a higher score means less disability.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change in the SF-36v2 Physical Composite Score (PCS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '101', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '101', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '2.37', 'spread': '0.647', 'groupId': 'OG000'}, {'value': '3.64', 'spread': '0.652', 'groupId': 'OG001'}, {'value': '1.58', 'spread': '0.663', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '24 Weeks', 'description': 'Change from baseline to Week 24/ET on the PCS of the 36-Item Short Form Health Survey version 2 (SF-36v2). The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire. The scale range is from 0-100. A lower score means more disability and a higher score means less disability.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change in Baseline to Week 24/ET as Measured by the Short-Form 36 Health Survey, Version 2 (SF-36v2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '102', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '101', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'Physical Functioning Score', 'categories': [{'measurements': [{'value': '1.07', 'spread': '1.039', 'groupId': 'OG000'}, {'value': '1.43', 'spread': '1.055', 'groupId': 'OG001'}, {'value': '0.04', 'spread': '1.067', 'groupId': 'OG002'}]}]}, {'title': 'Role Physical Score', 'categories': [{'measurements': [{'value': '0.92', 'spread': '1.057', 'groupId': 'OG000'}, {'value': '2.64', 'spread': '1.074', 'groupId': 'OG001'}, {'value': '0.16', 'spread': '1.082', 'groupId': 'OG002'}]}]}, {'title': 'Bodily Pain Score', 'categories': [{'measurements': [{'value': '0.94', 'spread': '1.172', 'groupId': 'OG000'}, {'value': '4.10', 'spread': '1.185', 'groupId': 'OG001'}, {'value': '1.8', 'spread': '1.201', 'groupId': 'OG002'}]}]}, {'title': 'General Health Score', 'categories': [{'measurements': [{'value': '0.55', 'spread': '1.091', 'groupId': 'OG000'}, {'value': '2.38', 'spread': '1.119', 'groupId': 'OG001'}, {'value': '-1.18', 'spread': '1.21', 'groupId': 'OG002'}]}]}, {'title': 'Vitality Score', 'categories': [{'measurements': [{'value': '1.13', 'spread': '1.142', 'groupId': 'OG000'}, {'value': '3.35', 'spread': '1.156', 'groupId': 'OG001'}, {'value': '1.81', 'spread': '1.168', 'groupId': 'OG002'}]}]}, {'title': 'Social Functioning Score', 'categories': [{'measurements': [{'value': '0.22', 'spread': '1.153', 'groupId': 'OG000'}, {'value': '2.05', 'spread': '1.173', 'groupId': 'OG001'}, {'value': '1.89', 'spread': '1.181', 'groupId': 'OG002'}]}]}, {'title': 'Role Emotional Score', 'categories': [{'measurements': [{'value': '-1.11', 'spread': '1.147', 'groupId': 'OG000'}, {'value': '1.2', 'spread': '1.169', 'groupId': 'OG001'}, {'value': '-0.32', 'spread': '1.178', 'groupId': 'OG002'}]}]}, {'title': 'Mental Health Score', 'categories': [{'measurements': [{'value': '-0.92', 'spread': '1.169', 'groupId': 'OG000'}, {'value': '0.75', 'spread': '1.188', 'groupId': 'OG001'}, {'value': '-0.69', 'spread': '1.194', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '24 Weeks', 'description': 'The SF-36v2 is a multipurpose, 36-item subject-completed validated questionnaire that measures 8 domains of health: physical functioning, role limitations due to physical health (RP), bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The SF-36v2 survey with a 4-week recall will be used. It yields scale scores for each of these 8 health domains , each of which is scored from 0 to 100. Higher scores indicate with a better health status, with 100 representing the highest level of functioning possible.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set'}, {'type': 'SECONDARY', 'title': 'Change in Depressive Symptoms From Baseline to Week 24/ET as Measured by Change in the Severity of Depression as Measured by the Quick Inventory of Depression Symptomatology (QIDS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '102', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.24', 'spread': '0.308', 'groupId': 'OG000'}, {'value': '-0.80', 'spread': '0.312', 'groupId': 'OG001'}, {'value': '-0.62', 'spread': '0.314', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '24 Weeks', 'description': 'The 16-item QIDS (Rush et al. 2003) is designed to assess the severity of depressive symptoms. The QIDS is available in a self-rated version and assesses all the criterion symptom domains designated by the American Psychiatry Association Diagnostic and Statistical Manual of Mental Disorders - 5th edition to diagnose a major depressive episode. The 7-day period prior to assessment is the usual time frame for assessing symptom severity. Scores range from 0 to 27, with higher scores indicating a worse outcome.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change in Olfactory Impairment From Baseline to Week 24/ET as Measured by the Smell Identification Test (SIT)™', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '93', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '2.47', 'spread': '0.765', 'groupId': 'OG000'}, {'value': '2.33', 'spread': '0.768', 'groupId': 'OG001'}, {'value': '-1.30', 'spread': '0.793', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '24 Weeks', 'description': "The SIT is a test comprised of 4 booklets each containing 10 microencapsulated (scratch and sniff) odors. Forced choice response alternatives to identify the odor accompany each test item. Each correct response is assigned a score of 1 and incorrect responses are assigned a score of 0. The total score is calculated by summing the scores of each individual odor for a total possible score ranging from 0-40. The higher the score, the better the individual's sense of smell. The test provides an absolute indication of smell loss (anosmia; mild, moderate or severe hyposmia) as well as an index to detect malingering.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change in Baseline to Week 24/ET as Measured by the Euroqol 5-dimension (EQ-5D) Instrument Visual Analogue Scale (VAS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '101', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '2.59', 'spread': '1.783', 'groupId': 'OG000'}, {'value': '3.97', 'spread': '1.791', 'groupId': 'OG001'}, {'value': '-0.35', 'spread': '1.810', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '24 Weeks', 'description': "The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The outcome measured for this study was the EQ VAS, which records the subject's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflects the subject's own judgement. VAS scores range from 0 (worst health you can imagine) to 100 (best health you can imagine).", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set. Only VAS Scores analyzed.'}, {'type': 'SECONDARY', 'title': 'Change in Baseline to Week 24/ET as Measured by the Short-Form 6-Dimension (SF-6D) Instrument', 'denoms': [{'units': 'Participants', 'counts': [{'value': '101', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '101', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'spread': '0.016', 'groupId': 'OG000'}, {'value': '0.04', 'spread': '0.017', 'groupId': 'OG001'}, {'value': '0.01', 'spread': '0.016', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '24 Weeks', 'description': 'The SF-6D is a single health state index derived from the 11 items from the SF-36v2. SF-6D scores range from 0 (worst health state) to 1 (best health state).', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set'}, {'type': 'SECONDARY', 'title': 'Comparison of Health Economic Measures- Percentage of Subjects Indicating That They Are Willing to Consider Sinus Surgery', 'denoms': [{'units': 'Participants', 'counts': [{'value': '104', 'groupId': 'OG000'}, {'value': '104', 'groupId': 'OG001'}, {'value': '102', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '63', 'groupId': 'OG000'}, {'value': '59', 'groupId': 'OG001'}, {'value': '54', 'groupId': 'OG002'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'value': '52', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '54', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline, Week 24', 'description': 'Percentage of subjects indicating that they are willing to consider Sinus Surgery', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set'}, {'type': 'SECONDARY', 'title': 'Comparison of Health Economic Measures- Percentage of Subjects Who Meet the Minimal Objective Criteria for Surgical Intervention', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '102', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '42', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '45', 'groupId': 'OG002'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'value': '30', 'groupId': 'OG000'}, {'value': '36', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline, Week 24', 'description': 'Percentage of Subjects who meet the minimal objective criteria for surgical intervention', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set'}, {'type': 'SECONDARY', 'title': 'Comparison of Health Economic Measures- Percentage of Subjects Approved for Surgery Who no Longer Elect to Undergo a Surgery', 'denoms': [{'units': 'Participants', 'counts': [{'value': '104', 'groupId': 'OG000'}, {'value': '104', 'groupId': 'OG001'}, {'value': '102', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '52', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Week 24', 'description': 'Outcome value presented here is the percent of subjects who are approved for surgery but no longer elect to undergo a surgery. The number of participants analyzed indicates the total number of participants for whom this analysis was completed.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set'}, {'type': 'SECONDARY', 'title': 'Change in Work Productivity From Baseline to Week 24/ET as Measured by the Health and Work Performance Questionnaire (HPQ).', 'denoms': [{'units': 'Participants', 'counts': [{'value': '81', 'groupId': 'OG000'}, {'value': '76', 'groupId': 'OG001'}, {'value': '75', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, Twice Daily (BID)'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, Twice Daily (BID)'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, Twice Daily (BID)'}], 'classes': [{'categories': [{'measurements': [{'value': '0.98', 'spread': '2.384', 'groupId': 'OG000'}, {'value': '-4.13', 'spread': '2.479', 'groupId': 'OG001'}, {'value': '-6.28', 'spread': '2.505', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': '24 Weeks', 'description': 'The Health and Work Performance Questionnaire measures work productivity (absenteeism and presenteeism). - Absenteeism is measured in missed work days over the past four weeks (range 0-20); absenteeism is measured in % productivity at work (0-100%), with higher values indicating improved productivity. Values for this outcome are reported as the change in relative absenteeism (the percentage of productivity at work) from baseline to Week 24.', 'unitOfMeasure': 'percentage of productivity', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set. Population size determined by the number of patients that completed the questionnaire at baseline and Week 24.'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Evaluation of Safety by Recording the Severity of Adverse Events (AEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '57', 'groupId': 'OG000'}, {'value': '52', 'groupId': 'OG001'}, {'value': '58', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'title': 'Mild', 'measurements': [{'value': '25', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}, {'title': 'Moderate', 'measurements': [{'value': '29', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}]}, {'title': 'Severe', 'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '24 Weeks', 'description': 'Assessment of safety by measuring severity of AEs using scale with 1=mild, 2=moderate, 3=severe', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set - Subjects with at least 1 AE'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Evaluation of Safety-Nasal Examination', 'denoms': [{'units': 'Participants', 'counts': [{'value': '108', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '103', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'Epistaxis', 'categories': [{'title': 'Present', 'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}, {'title': 'Absent', 'measurements': [{'value': '105', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '102', 'groupId': 'OG002'}]}]}, {'title': 'Septal Erosion/Perforation', 'categories': [{'title': 'Present', 'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}, {'title': 'Absent', 'measurements': [{'value': '105', 'groupId': 'OG000'}, {'value': '102', 'groupId': 'OG001'}, {'value': '103', 'groupId': 'OG002'}]}]}, {'title': 'Ulceration/Erosion (non-septum)', 'categories': [{'title': 'Present', 'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}, {'title': 'Absent', 'measurements': [{'value': '108', 'groupId': 'OG000'}, {'value': '103', 'groupId': 'OG001'}, {'value': '102', 'groupId': 'OG002'}]}]}, {'title': 'Mucosal Candidiasis', 'categories': [{'title': 'Present', 'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}, {'title': 'Absent', 'measurements': [{'value': '108', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '103', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '24 Weeks', 'description': 'Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Evaluation of Safety Measuring Vital Signs- Blood Pressure', 'denoms': [{'units': 'Participants', 'counts': [{'value': '109', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '104', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'Systolic Blood Pressure (mmHg)', 'categories': [{'measurements': [{'value': '127.3', 'spread': '14.15', 'groupId': 'OG000'}, {'value': '126.7', 'spread': '14.11', 'groupId': 'OG001'}, {'value': '127.3', 'spread': '14.69', 'groupId': 'OG002'}]}]}, {'title': 'Diastolic Blood Pressure (mmHg)', 'categories': [{'measurements': [{'value': '78.0', 'spread': '8.22', 'groupId': 'OG000'}, {'value': '78.2', 'spread': '9.70', 'groupId': 'OG001'}, {'value': '79.3', 'spread': '8.62', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': '24 Weeks', 'description': 'Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Evaluation of Safety Measuring Vital Signs- Pulse', 'denoms': [{'units': 'Participants', 'counts': [{'value': '109', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '104', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '73.7', 'spread': '11.96', 'groupId': 'OG000'}, {'value': '72.7', 'spread': '9.5', 'groupId': 'OG001'}, {'value': '73.1', 'spread': '9.45', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': '24 Weeks', 'description': 'Measure pulse in beats per minute (bpm)', 'unitOfMeasure': 'Beats per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Evaluation of Safety Measuring Vital Signs- Weight', 'denoms': [{'units': 'Participants', 'counts': [{'value': '109', 'groupId': 'OG000'}, {'value': '104', 'groupId': 'OG001'}, {'value': '104', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'categories': [{'measurements': [{'value': '82.81', 'spread': '20.873', 'groupId': 'OG000'}, {'value': '84.23', 'spread': '19.232', 'groupId': 'OG001'}, {'value': '83.84', 'spread': '21.531', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': '24 Weeks', 'description': 'Assessment of safety from physical examination-weight measured in kg or lb', 'unitOfMeasure': 'kg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Evaluation of Safety - Monitoring Concomitant Medication Usage', 'denoms': [{'units': 'Participants', 'counts': [{'value': '103', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}, {'value': '105', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}], 'classes': [{'title': 'Amides', 'categories': [{'measurements': [{'value': '33', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}]}]}, {'title': 'Adrenergics in Combination with Corticosteroids or other drugs', 'categories': [{'measurements': [{'value': '35', 'groupId': 'OG000'}, {'value': '30', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}]}]}, {'title': 'Ace Inhibitors, Plain', 'categories': [{'measurements': [{'value': '5', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}]}]}, {'title': 'Allergen Extracts', 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}, {'title': 'Alpha-Adrenoreceptor Antagonists', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '24 Weeks', 'description': 'Assessment for safety from the collection of information for concomitant medications usage', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Number of subjects receiving concomitant medications. Only top 5 con-meds are detailed below.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, Twice Daily (BID)'}, {'id': 'FG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, Twice Daily (BID)'}, {'id': 'FG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, Twice Daily (BID)'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '111'}, {'groupId': 'FG001', 'numSubjects': '109'}, {'groupId': 'FG002', 'numSubjects': '112'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '102'}, {'groupId': 'FG001', 'numSubjects': '101'}, {'groupId': 'FG002', 'numSubjects': '96'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '9'}, {'groupId': 'FG001', 'numSubjects': '8'}, {'groupId': 'FG002', 'numSubjects': '16'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '3'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '2'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '9'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}]}, {'type': 'Reason not provided', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '111', 'groupId': 'BG000'}, {'value': '109', 'groupId': 'BG001'}, {'value': '112', 'groupId': 'BG002'}, {'value': '332', 'groupId': 'BG003'}]}], 'groups': [{'id': 'BG000', 'title': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'BG001', 'title': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'BG002', 'title': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks\n\nOPN-375: OPN-375, BID'}, {'id': 'BG003', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '95', 'groupId': 'BG000'}, {'value': '93', 'groupId': 'BG001'}, {'value': '89', 'groupId': 'BG002'}, {'value': '277', 'groupId': 'BG003'}]}, {'title': '>=65 years', 'measurements': [{'value': '16', 'groupId': 'BG000'}, {'value': '16', 'groupId': 'BG001'}, {'value': '23', 'groupId': 'BG002'}, {'value': '55', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Age, Continuous', 'classes': [{'title': 'Mean', 'categories': [{'measurements': [{'value': '48.4', 'spread': '13.85', 'groupId': 'BG000'}, {'value': '49.6', 'spread': '13.49', 'groupId': 'BG001'}, {'value': '49.2', 'spread': '15.26', 'groupId': 'BG002'}, {'value': '49.1', 'spread': '14.19', 'groupId': 'BG003'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '47', 'groupId': 'BG000'}, {'value': '43', 'groupId': 'BG001'}, {'value': '51', 'groupId': 'BG002'}, {'value': '141', 'groupId': 'BG003'}]}, {'title': 'Male', 'measurements': [{'value': '64', 'groupId': 'BG000'}, {'value': '66', 'groupId': 'BG001'}, {'value': '61', 'groupId': 'BG002'}, {'value': '191', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '18', 'groupId': 'BG003'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '110', 'groupId': 'BG000'}, {'value': '100', 'groupId': 'BG001'}, {'value': '104', 'groupId': 'BG002'}, {'value': '314', 'groupId': 'BG003'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}]}, {'title': 'Asian', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '10', 'groupId': 'BG003'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Black or African American', 'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '20', 'groupId': 'BG003'}]}, {'title': 'White', 'measurements': [{'value': '99', 'groupId': 'BG000'}, {'value': '99', 'groupId': 'BG001'}, {'value': '101', 'groupId': 'BG002'}, {'value': '299', 'groupId': 'BG003'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'Canada', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}, {'value': '16', 'groupId': 'BG003'}]}]}, {'title': 'Sweden', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '8', 'groupId': 'BG003'}]}]}, {'title': 'United States', 'categories': [{'measurements': [{'value': '62', 'groupId': 'BG000'}, {'value': '64', 'groupId': 'BG001'}, {'value': '57', 'groupId': 'BG002'}, {'value': '183', 'groupId': 'BG003'}]}]}, {'title': 'Poland', 'categories': [{'measurements': [{'value': '33', 'groupId': 'BG000'}, {'value': '25', 'groupId': 'BG001'}, {'value': '32', 'groupId': 'BG002'}, {'value': '90', 'groupId': 'BG003'}]}]}, {'title': 'United Kingdom', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}]}]}, {'title': 'Georgia', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}]}]}, {'title': 'Bulgaria', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '7', 'groupId': 'BG003'}]}]}, {'title': 'Russia', 'categories': [{'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}, {'value': '24', 'groupId': 'BG003'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Intranasal corticosteroid treatment for chronic sinusitis within the last 10 years', 'classes': [{'title': 'Mometason Furoate', 'categories': [{'measurements': [{'value': '44', 'groupId': 'BG000'}, {'value': '51', 'groupId': 'BG001'}, {'value': '48', 'groupId': 'BG002'}, {'value': '143', 'groupId': 'BG003'}]}]}, {'title': 'Fluticasone proprionate', 'categories': [{'measurements': [{'value': '62', 'groupId': 'BG000'}, {'value': '66', 'groupId': 'BG001'}, {'value': '67', 'groupId': 'BG002'}, {'value': '195', 'groupId': 'BG003'}]}]}, {'title': 'Fluticasone Furoate', 'categories': [{'measurements': [{'value': '12', 'groupId': 'BG000'}, {'value': '14', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}, {'value': '46', 'groupId': 'BG003'}]}]}, {'title': 'Budesonide', 'categories': [{'measurements': [{'value': '18', 'groupId': 'BG000'}, {'value': '22', 'groupId': 'BG001'}, {'value': '18', 'groupId': 'BG002'}, {'value': '58', 'groupId': 'BG003'}]}]}, {'title': 'Ciclesonide', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}]}]}, {'title': 'Beclomethasone', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}, {'value': '18', 'groupId': 'BG003'}]}]}, {'title': 'Triamcinolone', 'categories': [{'measurements': [{'value': '14', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '16', 'groupId': 'BG002'}, {'value': '41', 'groupId': 'BG003'}]}]}, {'title': 'Flunisolide', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}]}]}, {'title': 'Fluticasone and azelastine', 'categories': [{'measurements': [{'value': '15', 'groupId': 'BG000'}, {'value': '14', 'groupId': 'BG001'}, {'value': '17', 'groupId': 'BG002'}, {'value': '46', 'groupId': 'BG003'}]}]}, {'title': 'Other', 'categories': [{'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '13', 'groupId': 'BG003'}]}]}, {'title': 'Any Treatment', 'categories': [{'measurements': [{'value': '100', 'groupId': 'BG000'}, {'value': '100', 'groupId': 'BG001'}, {'value': '104', 'groupId': 'BG002'}, {'value': '304', 'groupId': 'BG003'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Prior Sinusitis Surgery', 'classes': [{'title': 'Any surgery', 'categories': [{'measurements': [{'value': '58', 'groupId': 'BG000'}, {'value': '53', 'groupId': 'BG001'}, {'value': '58', 'groupId': 'BG002'}, {'value': '169', 'groupId': 'BG003'}]}]}, {'title': 'Endoscopic sinus surgery', 'categories': [{'measurements': [{'value': '52', 'groupId': 'BG000'}, {'value': '47', 'groupId': 'BG001'}, {'value': '48', 'groupId': 'BG002'}, {'value': '147', 'groupId': 'BG003'}]}]}, {'title': 'Balloon sinuplasty', 'categories': [{'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}, {'value': '14', 'groupId': 'BG003'}]}]}, {'title': 'Polypectomy alone', 'categories': [{'measurements': [{'value': '14', 'groupId': 'BG000'}, {'value': '12', 'groupId': 'BG001'}, {'value': '21', 'groupId': 'BG002'}, {'value': '47', 'groupId': 'BG003'}]}]}, {'title': 'Other surgery', 'categories': [{'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '10', 'groupId': 'BG003'}]}]}, {'title': 'Sinus stent', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '12', 'groupId': 'BG003'}]}]}, {'title': 'Propel mometasone furoate implant', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '12', 'groupId': 'BG003'}]}]}, {'title': 'Sinuva mometasone furoate sinus implant : Yes', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Other Chronic Sinusitis Treatment History', 'classes': [{'title': 'Systemic antibiotic in last 5 years', 'categories': [{'title': 'Yes', 'measurements': [{'value': '44', 'groupId': 'BG000'}, {'value': '48', 'groupId': 'BG001'}, {'value': '42', 'groupId': 'BG002'}, {'value': '134', 'groupId': 'BG003'}]}, {'title': 'No', 'measurements': [{'value': '67', 'groupId': 'BG000'}, {'value': '61', 'groupId': 'BG001'}, {'value': '70', 'groupId': 'BG002'}, {'value': '198', 'groupId': 'BG003'}]}]}, {'title': 'Saline lavage', 'categories': [{'title': 'Yes', 'measurements': [{'value': '36', 'groupId': 'BG000'}, {'value': '50', 'groupId': 'BG001'}, {'value': '39', 'groupId': 'BG002'}, {'value': '125', 'groupId': 'BG003'}]}, {'title': 'No', 'measurements': [{'value': '75', 'groupId': 'BG000'}, {'value': '59', 'groupId': 'BG001'}, {'value': '73', 'groupId': 'BG002'}, {'value': '207', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'History of treatment for Chronic Sinusitis other than corticosteroids and surgery.', 'unitOfMeasure': 'Participants'}, {'title': 'Sinus imaging in last year', 'classes': [{'title': 'CT scans', 'categories': [{'title': '0', 'measurements': [{'value': '64', 'groupId': 'BG000'}, {'value': '59', 'groupId': 'BG001'}, {'value': '54', 'groupId': 'BG002'}, {'value': '177', 'groupId': 'BG003'}]}, {'title': '1', 'measurements': [{'value': '40', 'groupId': 'BG000'}, {'value': '42', 'groupId': 'BG001'}, {'value': '50', 'groupId': 'BG002'}, {'value': '132', 'groupId': 'BG003'}]}, {'title': '2', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '22', 'groupId': 'BG003'}]}, {'title': '3', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}]}]}, {'title': 'MRI scans', 'categories': [{'title': '0', 'measurements': [{'value': '107', 'groupId': 'BG000'}, {'value': '106', 'groupId': 'BG001'}, {'value': '105', 'groupId': 'BG002'}, {'value': '318', 'groupId': 'BG003'}]}, {'title': '1', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}, {'value': '14', 'groupId': 'BG003'}]}, {'title': '2', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': '3', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Smoking History', 'classes': [{'title': 'Current cigarette smoker', 'categories': [{'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '14', 'groupId': 'BG003'}]}]}, {'title': 'Current smoker (other forms of tobacco)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2022-01-07', 'size': 1040028, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2023-04-04T12:53', 'hasProtocol': True}, {'date': '2022-02-14', 'size': 904417, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2023-04-04T12:56', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 332}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-11-27', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-05', 'completionDateStruct': {'date': '2022-01-19', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-05-01', 'studyFirstSubmitDate': '2018-12-18', 'resultsFirstSubmitDate': '2023-06-15', 'studyFirstSubmitQcDate': '2018-12-18', 'lastUpdatePostDateStruct': {'date': '2024-05-29', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2023-09-12', 'studyFirstPostDateStruct': {'date': '2018-12-20', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2023-09-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-01-19', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Evaluation of Safety by Recording the Severity of Adverse Events (AEs)', 'timeFrame': '24 Weeks', 'description': 'Assessment of safety by measuring severity of AEs using scale with 1=mild, 2=moderate, 3=severe'}, {'measure': 'Evaluation of Safety-Nasal Examination', 'timeFrame': '24 Weeks', 'description': 'Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum.'}, {'measure': 'Evaluation of Safety Measuring Vital Signs- Blood Pressure', 'timeFrame': '24 Weeks', 'description': 'Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)'}, {'measure': 'Evaluation of Safety Measuring Vital Signs- Pulse', 'timeFrame': '24 Weeks', 'description': 'Measure pulse in beats per minute (bpm)'}, {'measure': 'Evaluation of Safety Measuring Vital Signs- Weight', 'timeFrame': '24 Weeks', 'description': 'Assessment of safety from physical examination-weight measured in kg or lb'}, {'measure': 'Evaluation of Safety - Monitoring Concomitant Medication Usage', 'timeFrame': '24 Weeks', 'description': 'Assessment for safety from the collection of information for concomitant medications usage'}], 'primaryOutcomes': [{'measure': 'Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior and/or Posterior) at the End of Week 4', 'timeFrame': '4 Weeks', 'description': 'Change from baseline to the end of Week 4 in average total instantaneous AM scores (evaluation of symptom severity immediately preceding the time of scoring) for each symptom: nasal congestion, nasal discharge (anterior and/or posterior), facial pain/pressure sensation. Baseline scores are the averaged total instantaneous AM scores over the last 7 days of the single blind run in period, and the end of Week 4, scores are averaged over the 7 days from the subject diary. Range of scores for each nasal symptom is 0= none, 1 = mild, 2 = moderate, 3 = severe. Composite score is a sum of the 3 symptom scores and will range from 0 to 9.'}, {'measure': 'Change From Baseline to Week 24/Early Termination (ET) in the Average Percent of the Volume Opacified in the Ethmoid and Maxillary Sinuses', 'timeFrame': 'Baseline, Week 24', 'description': 'Change from baseline to Week 24/ET in the average percent of ethmoid and maxillary sinus volume opacified as measured by CT. Percent volume opacified can range from 0% to 100%. Outcome measure is the percentage change from percent opacification at baseline to percent opacification at Week 24; therefore, change in opacification volume can range from -100% to 100%. For example, if Baseline opacification was 68.22% and Week 24 opacification was 66.11%, then the change would be reported as -2.11%.'}], 'secondaryOutcomes': [{'measure': 'Change From Baseline to Defined Timepoint - Subject Symptoms and Functioning as Measured by the Sinonasal Outcome Test - 22-item (SNOT-22) Total Score and Sub Domains', 'timeFrame': 'Week 24', 'description': 'The SNOT-22 is a subject-completed questionnaire that consists of 22 symptoms and social/emotional consequences of their nasal disorder across several domains including: rhinologic, ear/facial pain, psychological dysfunction, and sleep dysfunction. Total scores range from 0-110. Each item is rated as follows: 0=no problem, 1=very mild problem, 2=mild or slight problem,3=moderate problem, 4=severe problem, 5=problem as bad as it can be.'}, {'measure': 'Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior and/or Posterior)', 'timeFrame': 'Week 12', 'description': 'Change from baseline in average total instantaneous AM scores (evaluation of symptom severity immediately preceding the time of scoring) for each symptom: nasal congestion, nasal discharge (anterior and/or posterior), facial pain/pressure sensation. Baseline scores are the averaged total instantaneous AM scores over the last 7 days of the single blind run in period, and the end of Week 4, scores are averaged over the 7 days from the subject diary. Range of scores for each nasal symptom is 0= none, 1 = mild, 2 = moderate, 3 = severe. Composite score is a sum of the 3 symptom scores and will range from 0 to 9.'}, {'measure': 'Change From Baseline in Nasal Congestion Measured by AM and PM Diary Symptom Scores', 'timeFrame': '12 Weeks', 'description': 'Subjects will report both instantaneous (evaluation of symptom severity immediately preceding the time of scoring) and reflective (evaluation of symptom severity over the past 12 hours), The Nasal Symptom Scale scores as 0=none, 1=mild-symptoms clearly present but minimal awareness, and easily tolerated, 2= moderate - definite awareness of symptoms that is bothersome but tolerable, 3 = severe - symptoms that are hard to tolerate, cause interference with activities or daily living.'}, {'measure': 'Change in Sense of Smell Scores Measured by AM and PM Diary Symptom Scores', 'timeFrame': '12 Weeks', 'description': 'Subjects will report both instantaneous (evaluation of symptom severity immediately preceding the time of scoring) and reflective (evaluation of symptom severity over the past 12 hours) The sense of smell scored as 0= normal, 1=slightly impaired, 2=moderately impaired, 3=absent. The change reported in the results is calculated by subtracting the score reported at Baseline from the score reported at Visit 4 (Week 12).'}, {'measure': 'Change From Baseline in Nasal Discharge (Anterior and/or Posterior) Measured by AM and PM Diary Symptom Scores', 'timeFrame': '12 Weeks', 'description': 'Subjects will report both instantaneous (evaluation of symptom severity immediately preceding the time of scoring) and reflective (evaluation of symptom severity over the past 12 hours). The Nasal Symptom Scale scores as 0=none, 1=mild-symptoms clearly present but minimal awareness, and easily tolerated, 2= moderate - definite awareness of symptoms that is bothersome but tolerable, 3 = severe - symptoms that are hard to tolerate, cause interference with activities or daily living.'}, {'measure': 'Change in Facial Pain or Pressure Sensation Measured by AM and PM Diary Symptom Scores', 'timeFrame': '12 Weeks', 'description': 'Subjects will report both instantaneous (evaluation of symptom severity immediately preceding the time of scoring) and reflective (evaluation of symptom severity over the past 12 hours). The Nasal Symptom Scale scores as 0=none, 1=mild-symptoms clearly present but minimal awareness, and easily tolerated, 2= moderate - definite awareness of symptoms that is bothersome but tolerable, 3 = severe - symptoms that are hard to tolerate, cause interference with activities or daily living.\n\nThe value reported in the results is calculated by subtracting the score reported by the patient at Baseline from the score reported by the patient at Visit 4 (Week 12).'}, {'measure': 'Change From Baseline to Week 24/Early Termination (ET) in the Average Percent of the Volume Opacified in the Ethmoid and Maxillary Sinuses Among Patient Populations', 'timeFrame': '24 Weeks', 'description': 'Change from baseline to Week 24/ET in the average percent of ethmoid and maxillary sinus volume opacified as measured by CT for CRS with Nasal Polyps (NP) and without NP sub-groups and in patients with and without previous sinus surgery. Percent volume opacified can range from 0% to 100%. Outcome measure is percentage change from percent opacification at baseline to percent opacification at Week 24; therefor, change in opacification volume can range from -100% to 100%. For example, if Baseline opacification was 68.22% and Week 24 opacification was 66.11%, then the change would be reported as -2.11%.'}, {'measure': 'Change From Baseline to Week 24/ET in the Lund-Mackay Staging System Total Score', 'timeFrame': 'Baseline, Week 24', 'description': 'Lund-Mackay Staging System: Lund-Mackay (LM) system (Lund and Mackay, 1993) assigns to each of 10 sinus cavities (left and right maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal) a score of 0 (no opacification), 1 (partial opacification), or 2 (total opacification), plus a 0-2 score for each of the left and right ostiomeatal complex (OMC). The total LM score for a CT scan ranges from 0-24.'}, {'measure': 'Change From Baseline to Week24/ET in the Lund-Mackay Staging System Total Scores for Ethmoids and Maxillary Sinuses Combined', 'timeFrame': '24 Weeks', 'description': 'Lund-Mackay Staging System: Lund-Mackay (LM) system (Lund and Mackay, 1993) assigns to each of 10 sinus cavities (left and right maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal) a score of 0 (no opacification), 1 (partial opacification), or 2 (total opacification), plus a 0-2 score for the ostiomeatal complex (OMC).\n\nThe values reported for this outcome are the change in total opacification of the left and right maxillary and ethmoid sinuses (Visit 6 \\[Wk 24\\] score minus Baseline score). Each visit score can range from a total of 0-12 (sum of 0-2 score assigned for each of left and right maxillary, left and right anterior ethmoid, and left and right posterior ethmoid).'}, {'measure': 'Change From Baseline to Week24/ET in the Lund-Mackay Staging System Total Scores for Sinus Pairs', 'timeFrame': 'Week 24', 'description': 'Lund-Mackay Staging System: Lund-Mackay (LM) system (Lund and Mackay, 1993) assigns to each of 10 sinus cavities (left and right maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal) a score of 0 (no opacification), 1 (partial opacification), or 2 (total opacification), plus a 0-2 score for the ostiomeatal complex (OMC).\n\nEach sinus pair (left and right side) listed below can achieve a total score of 0-4 (sum of 0-2 for each side). The values reported below are calculated by subtracting the total score at Baseline from the total score at Visit 6 (Wk 24).'}, {'measure': 'Change From Baseline to Week 24/ET in Average Percent of Sinus Volume Occupied by Disease in the Worst Maxillary Sinus as Measured by CT Scan Assessment', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Change From Baseline to Week 24/ET in Average Percent of Sinus Volume Occupied by Disease in the Worst Ethmoid Sinus as Measured by CT Scan Assessment', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Change From Baseline to Week 24/ET in Average Percent of Sinus Volume Occupied by Disease in the Worst Sinus Between the Maxillary and Ethmoid Sinuses as Measured by CT Scan Assessment Among Patient Populations', 'timeFrame': '24 Weeks', 'description': 'Percent of sinus volume occupied by disease in the worst sinus between maxillary and ethmoid sinuses for the total population, chronic rhinosinusitis with nasal polyps (CRSwNP) subgroup, chronic rhinosinusitis without nasal polyps (CRSsNP) subgroup, patients with previous sinus surgery subgroup, and without previous surgery subgroup.'}, {'measure': 'Change From Baseline to Week 24/ET in the Zeinrich Modification of Lund-Mackay Staging System Total Score', 'timeFrame': 'Baseline, Week 24', 'description': 'Zeinrich Modification of the Lund-Mackay Staging System:\n\nZeinrich modified the LM system by creating subdivisions within "partial opacification" and increasing the range of scores to 0-5 based on percent opacification: 0 = 0%, 1 = 1%-25%, 2 = 26%-50%, 3 = 51%-75%, 4 = 76%- 99%, and 5 = 100% for each sinus. Total score ranges from 0 to 50.'}, {'measure': 'Change From Baseline to Week 24/ET in the Zeinrich Modification of Lund-Mackay Staging System for Ethmoids and Maxillary Sinuses Combined', 'timeFrame': 'Baseline, Week 24', 'description': 'Zeinrich Modification of the Lund-Mackay Staging System:\n\nZeinrich modified the LM system by creating subdivisions within "partial opacification" and increasing the range of scores to 0-5 based on percent opacification: 0 = 0%, 1 = 1%-25%, 2 = 26%-50%, 3 = 51%-75%, 4 = 76%- 99%, and 5 = 100% The total score for the combined ethmoids and maxillary sinuses can range from 0-30 (0-5 for each left and right of the anterior ethmoid, posterior ethmoid, and maxillary sinuses). The outcome values presented in the results are determined by subtracting the total score at Baseline from the total score at Week 24.'}, {'measure': 'Change From Baseline to Week 24/ET in the Zeinrich Modification of Lund-Mackay Staging System for the Sinus Pairs', 'timeFrame': 'Baseline, Week 24', 'description': 'Zeinrich Modification of the Lund-Mackay Staging System:\n\nZeinrich modified the LM system by creating subdivisions within "partial opacification" and increasing the range of scores to 0-5 based on percent opacification: 0 = 0%, 1 = 1%-25%, 2 = 26%-50%, 3 = 51%-75%, 4 = 76%- 99%, and 5 = 100% Each sinus pair (left and right side) listed below can achieve a total score of 0-10 (sum of score on each side). The values reported for this outcome calculated by subtracting the score at Baseline from the score at Visit 6 (Wk 24).'}, {'measure': 'Change From Baseline to Week 24/ET in the Zeinrich Modification of Lund-Mackay Staging System for the Worst Sinus Between Maxillary and Ethmoid Sinuses Among Patient Populations', 'timeFrame': 'Baseline, Week 24', 'description': 'Zeinrich Modification of the Lund-Mackay Staging System:\n\nZeinrich modified the LM system by creating subdivisions within "partial opacification" and increasing the range of scores to 0-5 based on percent opacification: 0 = 0%, 1 = 1%-25%, 2 = 26%-50%, 3 = 51%-75%, 4 = 76%- 99%, and 5 = 100%'}, {'measure': 'Time Comparison to First Acute Exacerbation of Chronic Sinusitis', 'timeFrame': '24 Weeks', 'description': 'Comparing the distribution of time to first acute exacerbation of chronic sinusitis, defined as a worsening of symptoms that requires escalation of treatment'}, {'measure': 'Percentage of Subjects Requiring Rescue Medication After Week 4', 'timeFrame': '8 Weeks', 'description': 'Recording of each dose of approved rescue medication after the Week 4 visit through Week 12'}, {'measure': 'Change in Sleep Quality as Measured by the Pittsburgh Sleep Quality Index (PSQI)', 'timeFrame': '12 Weeks, 24 Weeks', 'description': 'The PSQI is a validated, self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate 7 "component" scores (each ranging between 0 and 3): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these 7 components yields 1 global score ranging between 0 and 21. Higher values represent a worse outcome.'}, {'measure': 'Change in Overall Health From Baseline to Week 4 and Week 24/ET as Measured by the Percent of Subjects Improved as Indicated by the Patient Global Impression of Change (PGIC)', 'timeFrame': 'Week 4, Week 24', 'description': 'Global impression of change will be assessed using a subject-completed PGIC scale range: 1 - Very much improved, 2 - Much improved, 3 - Minimally improved, 4 - No change, 5 - Minimally worse, 6 - Much worse, 7 - Very much worse'}, {'measure': 'Severity of Depression at Week 24 as Measured by the Quick Inventory of Depression Symptomatology (QIDS)', 'timeFrame': 'Week 24', 'description': 'The 16-item QIDS (Rush et al. 2003) is designed to assess the severity of depressive symptoms. The QIDS is available in a self-rated version and assesses all the criterion symptom domains designated by the American Psychiatry Association Diagnostic and Statistical Manual of Mental Disorders - 5th edition to diagnose a major depressive episode. The 7-day period prior to assessment is the usual time frame for assessing symptom severity. Scores range from 0 to 27, where higher scores indicate a worse outcome.'}, {'measure': 'Change in the 36-Item Short Form Health Survey Version 2 (SF-36v2) Mental Composite Score (MCS)', 'timeFrame': '24 Weeks', 'description': 'Change from baseline to Week 24/ET on the MCS of the 36-Item Short Form Health Survey version 2 (SF-36v2). The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire. The scale range is from 0-100. A lower score means more disability and a higher score means less disability.'}, {'measure': 'Change in the SF-36v2 Physical Composite Score (PCS)', 'timeFrame': '24 Weeks', 'description': 'Change from baseline to Week 24/ET on the PCS of the 36-Item Short Form Health Survey version 2 (SF-36v2). The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire. The scale range is from 0-100. A lower score means more disability and a higher score means less disability.'}, {'measure': 'Change in Baseline to Week 24/ET as Measured by the Short-Form 36 Health Survey, Version 2 (SF-36v2)', 'timeFrame': '24 Weeks', 'description': 'The SF-36v2 is a multipurpose, 36-item subject-completed validated questionnaire that measures 8 domains of health: physical functioning, role limitations due to physical health (RP), bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The SF-36v2 survey with a 4-week recall will be used. It yields scale scores for each of these 8 health domains , each of which is scored from 0 to 100. Higher scores indicate with a better health status, with 100 representing the highest level of functioning possible.'}, {'measure': 'Change in Depressive Symptoms From Baseline to Week 24/ET as Measured by Change in the Severity of Depression as Measured by the Quick Inventory of Depression Symptomatology (QIDS)', 'timeFrame': '24 Weeks', 'description': 'The 16-item QIDS (Rush et al. 2003) is designed to assess the severity of depressive symptoms. The QIDS is available in a self-rated version and assesses all the criterion symptom domains designated by the American Psychiatry Association Diagnostic and Statistical Manual of Mental Disorders - 5th edition to diagnose a major depressive episode. The 7-day period prior to assessment is the usual time frame for assessing symptom severity. Scores range from 0 to 27, with higher scores indicating a worse outcome.'}, {'measure': 'Change in Olfactory Impairment From Baseline to Week 24/ET as Measured by the Smell Identification Test (SIT)™', 'timeFrame': '24 Weeks', 'description': "The SIT is a test comprised of 4 booklets each containing 10 microencapsulated (scratch and sniff) odors. Forced choice response alternatives to identify the odor accompany each test item. Each correct response is assigned a score of 1 and incorrect responses are assigned a score of 0. The total score is calculated by summing the scores of each individual odor for a total possible score ranging from 0-40. The higher the score, the better the individual's sense of smell. The test provides an absolute indication of smell loss (anosmia; mild, moderate or severe hyposmia) as well as an index to detect malingering."}, {'measure': 'Change in Baseline to Week 24/ET as Measured by the Euroqol 5-dimension (EQ-5D) Instrument Visual Analogue Scale (VAS)', 'timeFrame': '24 Weeks', 'description': "The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The outcome measured for this study was the EQ VAS, which records the subject's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflects the subject's own judgement. VAS scores range from 0 (worst health you can imagine) to 100 (best health you can imagine)."}, {'measure': 'Change in Baseline to Week 24/ET as Measured by the Short-Form 6-Dimension (SF-6D) Instrument', 'timeFrame': '24 Weeks', 'description': 'The SF-6D is a single health state index derived from the 11 items from the SF-36v2. SF-6D scores range from 0 (worst health state) to 1 (best health state).'}, {'measure': 'Comparison of Health Economic Measures- Percentage of Subjects Indicating That They Are Willing to Consider Sinus Surgery', 'timeFrame': 'Baseline, Week 24', 'description': 'Percentage of subjects indicating that they are willing to consider Sinus Surgery'}, {'measure': 'Comparison of Health Economic Measures- Percentage of Subjects Who Meet the Minimal Objective Criteria for Surgical Intervention', 'timeFrame': 'Baseline, Week 24', 'description': 'Percentage of Subjects who meet the minimal objective criteria for surgical intervention'}, {'measure': 'Comparison of Health Economic Measures- Percentage of Subjects Approved for Surgery Who no Longer Elect to Undergo a Surgery', 'timeFrame': 'Week 24', 'description': 'Outcome value presented here is the percent of subjects who are approved for surgery but no longer elect to undergo a surgery. The number of participants analyzed indicates the total number of participants for whom this analysis was completed.'}, {'measure': 'Change in Work Productivity From Baseline to Week 24/ET as Measured by the Health and Work Performance Questionnaire (HPQ).', 'timeFrame': '24 Weeks', 'description': 'The Health and Work Performance Questionnaire measures work productivity (absenteeism and presenteeism). - Absenteeism is measured in missed work days over the past four weeks (range 0-20); absenteeism is measured in % productivity at work (0-100%), with higher values indicating improved productivity. Values for this outcome are reported as the change in relative absenteeism (the percentage of productivity at work) from baseline to Week 24.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Chronic Rhinosinusitis']}, 'descriptionModule': {'briefSummary': 'This is a 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of intranasal administration of 186 and 372 μg twice daily (BID) of OPN-375 in subjects with chronic rhinosinusitis (CS) with or without nasal polyps.', 'detailedDescription': 'The primary objective of this study is to compare the efficacy of intranasal administration of twice-daily doses of 186 and 372 µg of OPN-375 (fluticasone propionate) with placebo in subjects with chronic rhinosinusitis using the following co-primary endpoints:\n\n1. A change from baseline in symptoms as measured by a composite score of nasal congestion, facial pain or pressure sensation, and nasal discharge (anterior and/or posterior) at the end of Week 4.\n2. A change from baseline to Week 24/Early Termination (ET) in the average percent of the volume opacified in the ethmoid and maxillary sinuses.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Potential subjects must meet the following criteria to enter this study:\n\n1. men or women aged 18 years and older at baseline visit\n2. women of childbearing potential must be abstinent, or if sexually active,\n\n 1. be practicing an effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method \\[eg, condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel\\], or male partner sterilization) before entry and throughout the study, or\n 2. be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or\n 3. be postmenopausal (amenorrhea for at least 1 year)\n3. women of child-bearing potential must have a negative urine pregnancy test at Visit 1 (Screening)\n4. must have a history of chronic rhinosinusitis (CRS) and be currently experiencing 2 or more of the following symptoms, 1 of which has to be either nasal congestion or nasal discharge (anterior and/or posterior nasal discharge) for equal to or greater than 12 weeks:\n\n * nasal congestion\n * nasal discharge (anterior and/or posterior nasal discharge)\n * facial pain or pressure\n * reduction or loss of smell\n5. endoscopic evidence of nasal mucosal disease, with edema, purulent discharge, or polyps in middle meatus, bilaterally, or presence of bilateral disease on a prior computed tomography (CT) scan performed within 14 days of Visit 1\n6. must have confirmatory evidence via a CT scan of bilateral sinus disease (have at least 1 sinus on each side of nose with a Lund-Mackay score of ≥1)\n7. baseline CT scan must show a combined ≥25% opacification of the ethmoid sinuses and ≥25% opacification of at least 1 maxillary sinus\n8. must have at least moderate symptoms (as defined in protocol) of nasal congestion as reported by the subject, on average, for the 7-day period preceding Visit 1 (Screening) run-in\n9. must have an average morning score of at least 1.5 for congestion on the Nasal Symptom Scale (as defined in protocol) recorded on the subject diary over a 7-day period during the first 14 days of the single-blind run-in period\n10. must demonstrate an ability to correctly complete the daily diary during the run-in period to be eligible for randomization\n11. Subjects with comorbid asthma or chronic obstructive pulmonary disorder (COPD) must be stable with no exacerbations (eg, no emergency room visits, hospitalizations, or oral or parenteral steroid use) within the 3 months before Visit 1 (Screening). Inhaled corticosteroid use must be limited to stable doses of no more than 1,000 μg/day of beclomethasone (or equivalent) for at least 3 months before Visit 1 (Screening) with plans to continue use throughout the study.\n12. Subjects with aspirin-exacerbated respiratory disease, who have undergone aspirin desensitization and are receiving daily aspirin therapy, must be receiving therapy for at least 6 months prior to Visit 1.\n13. must be able to cease treatment with intranasal steroids, inhaled corticosteroids (except permitted doses listed above for asthma and COPD) at the screening visit\n14. must be able to cease treatment with oral and nasal decongestants and antihistamines at Visit 1 (Screening)\n15. must be able to use the exhalation delivery system (EDS) correctly; all subjects will be required to demonstrate correct use with the practice EDS at Visit 1 (Screening).\n16. must be capable, in the opinion of the investigator, of providing informed consent to participate in the study. Subjects must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.\n\nPotential subjects who meet any of the following criteria will be excluded from entering this study:\n\n1. women who are pregnant or lactating\n2. inability to have each nasal cavity examined for any reason, including nasal septum deviation\n3. inability to achieve bilateral nasal airflow\n4. is currently taking XHANCE®\n5. have previously used XHANCE for more than 1 month and did not achieve an adequate symptomatic response\n6. the nasal/sinus anatomy prevents the accurate assessment of sinus volume via CT scan\n7. history of sinus or nasal surgery within 6 months before Visit 1 or has not healed from a prior sinus or nasal surgery\n8. have current evidence of odontogenic sinusitis, sinus mucocele (the affected sinus is completely opacified and either the margins are expanded and/or thinned OR there are areas of complete bone resorption resulting in bony defect and extension of the "mass" into adjacent tissues), evidence of allergic fungal sinusitis, or evidence of complicated sinus disease (including, but not limited to, extension of inflammation outside of the sinuses and nasal cavity)\n9. have a paranasal sinus or nasal tumor\n10. have a polyp extending outside the ostiomeatal complex/middle turbinate (anterior or inferior) that is below the inferior turbinate attachment as determined by the nasoendoscopy at screening\n11. have a nasal septum perforation\n12. have had more than 1 episode of epistaxis with frank bleeding in the month before Visit 1 (Screening)\n13. have evidence of significant mucosal injury, ulceration (eg, exposed cartilage) on Visit 1 (Screening) nasal examination/nasoendoscopy\n14. have current, ongoing rhinitis medicamentosa (rebound rhinitis)\n15. have significant oral structural abnormalities (eg, a cleft palate)\n16. have a diagnosis of cystic fibrosis\n17. history of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) or dyskinetic ciliary syndromes\n18. Symptom resolution or last dose of antibiotics for purulent nasal infection, acute sinusitis, or upper respiratory tract infection, influenza, or SARS-CoV-2 (COVID-19) has not occurred before Visit 1 or was less than 4 weeks before the CT scan. Potential subjects presenting with any of these infections may be rescreened 4 weeks after symptom resolution.\n19. planned sinonasal surgery during the period of the study\n20. allergy, hypersensitivity, or contraindication to corticosteroids or steroids\n21. has used oral steroids in the past for treatment of CRS and did not experience any relief of symptoms\n22. has a steroid eluting sinus stent still in place within 30 days of Visit 1\n23. allergy or hypersensitivity to any excipients in study drug\n24. exposure to any glucocorticoid treatment with potential for systemic effects (eg, oral, parenteral, intra-articular, or epidural steroids, high dose topical steroids) within 1 month before Visit 1 (Screening); except as noted in inclusion criteria for subjects with comorbid asthma or COPD\n25. have nasal candidiasis\n26. history or current diagnosis of any form of glaucoma or ocular hypertension\n27. history of intraocular pressure (IOP) elevation on any form of steroid therapy\n28. history or current diagnosis of the presence (in either eye) of a cataract unless both natural intraocular lenses have been removed\n29. history of immunodeficiency\n30. any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject\'s participation or compliance in the study\n31. have a positive drug screen or a recent (within 1 year of Visit 1 \\[Screening\\]) history of drug or alcohol abuse, or dependence that, in the opinion of the investigator could interfere with the subject\'s participation or compliance in the study\n32. have participated in an investigational drug clinical trial within 30 days of Visit 1 (Screening)\n33. have received mepolizumab (Nucala®), reslizumab (Cinquair®), dupilumab (Dupixent®), omalizumab (Xolair®), or benralizumab (Fasenra™) within 6 months of Visit 1 (Screening)\n34. is using strong cytochrome P450 3A4 (CYP3A4) inhibitor (eg, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin, conivaptan, lopinavir, voriconazole, cobicistat)\n35. is an employee of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, or is a family member of the employee or the investigator\n36. Patients who report unexplained worsening of vision within the past 3 months (e.g. difficulty reading or seeing traffic signs from a distance.). A diagnosis of presbyopia established by an eye doctor is not exclusionary'}, 'identificationModule': {'nctId': 'NCT03781804', 'briefTitle': 'Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps', 'organization': {'class': 'INDUSTRY', 'fullName': 'Optinose US Inc.'}, 'officialTitle': 'A 24-Week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (BID) in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps', 'orgStudyIdInfo': {'id': 'OPN-FLU-CS-3205'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'OPN-375 186 μg BID', 'description': 'OPN-375 186 μg BID x 24 Weeks', 'interventionNames': ['Drug: OPN-375']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'OPN-375 372 μg BID', 'description': 'OPN-375 372 μg BID x 24 Weeks', 'interventionNames': ['Drug: OPN-375']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Matching Placebo BID x 24 Weeks', 'interventionNames': ['Drug: OPN-375']}], 'interventions': [{'name': 'OPN-375', 'type': 'DRUG', 'description': 'OPN-375, BID', 'armGroupLabels': ['OPN-375 186 μg BID', 'OPN-375 372 μg BID', 'Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85234', 'city': 'Gilbert', 'state': 'Arizona', 'country': 'United States', 'facility': 'AZ Allergy & Immunology Research', 'geoPoint': {'lat': 33.35283, 'lon': -111.78903}}, {'zip': '93301', 'city': 'Bakersfield', 'state': 'California', 'country': 'United States', 'facility': 'Kern Research', 'geoPoint': {'lat': 35.37329, 'lon': -119.01871}}, {'zip': '95630', 'city': 'Folsom', 'state': 'California', 'country': 'United States', 'facility': 'Sacramento Ear, Nose & Throat Surgical and Medical Group Inc', 'geoPoint': {'lat': 38.67796, 'lon': -121.17606}}, {'zip': '92647', 'city': 'Huntington Beach', 'state': 'California', 'country': 'United States', 'facility': 'Allergy & Asthma Specialists Medical Group', 'geoPoint': {'lat': 33.6603, 'lon': -117.99923}}, {'zip': '90025', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Jonathan Corren, MD, Clinical Research Division', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '95661', 'city': 'Roseville', 'state': 'California', 'country': 'United States', 'facility': 'Sacramento Ear, Nose & Throat', 'geoPoint': {'lat': 38.75212, 'lon': -121.28801}}, {'zip': '95817', 'city': 'Sacramento', 'state': 'California', 'country': 'United States', 'facility': 'UC Davis Medical Center', 'geoPoint': {'lat': 38.58157, 'lon': -121.4944}}, {'zip': '95117', 'city': 'San Jose', 'state': 'California', 'country': 'United States', 'facility': 'Allergy and Asthma Associates of Santa Clara Valley', 'geoPoint': {'lat': 37.33939, 'lon': -121.89496}}, {'zip': '90503', 'city': 'Torrance', 'state': 'California', 'country': 'United States', 'facility': 'Breathe Clear Institute', 'geoPoint': {'lat': 33.83585, 'lon': -118.34063}}, {'zip': '94598', 'city': 'Walnut Creek', 'state': 'California', 'country': 'United States', 'facility': 'Allergy & Asthma Clinical Research', 'geoPoint': {'lat': 37.90631, 'lon': -122.06496}}, {'zip': '80909', 'city': 'Colorado Springs', 'state': 'Colorado', 'country': 'United States', 'facility': 'Colorado ENT & Allergy', 'geoPoint': {'lat': 38.83388, 'lon': -104.82136}}, {'zip': '06519', 'city': 'New Haven', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Yale School of Medicine Section of Otolaryngology', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'zip': '30308', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Emory University MOT', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Northwestern Memorial Hospital', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '60612', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Rush University Medical Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '60637', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'The University of Chicago', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '61761', 'city': 'Normal', 'state': 'Illinois', 'country': 'United States', 'facility': 'Midwest Allergy Sinus Asthma', 'geoPoint': {'lat': 40.5142, 'lon': -88.99063}}, {'zip': '47150', 'city': 'New Albany', 'state': 'Indiana', 'country': 'United States', 'facility': 'Advanced ENT and Allergy', 'geoPoint': {'lat': 38.28562, 'lon': -85.82413}}, {'zip': '50312-3505', 'city': 'Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'Iowa Head & Neck', 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'zip': '40205', 'city': 'Louisville', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Kentuckiana Ear Nose & Throat', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '70121', 'city': 'New Orleans', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Ochsner Clinic Foundation', 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'zip': '21287', 'city': 'Baltimore', 'state': 'Maryland', 'country': 'United States', 'facility': 'John Hopkins Hospital', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'zip': '21204', 'city': 'Towson', 'state': 'Maryland', 'country': 'United States', 'facility': 'Ear, Nose and Throat Associates at Greater Baltimore Medical Center', 'geoPoint': {'lat': 39.4015, 'lon': -76.60191}}, {'zip': '56303', 'city': 'Saint Cloud', 'state': 'Minnesota', 'country': 'United States', 'facility': 'St. Cloud Ear, Nose & Throat', 'geoPoint': {'lat': 45.5608, 'lon': -94.16249}}, {'zip': '65212', 'city': 'Columbia', 'state': 'Missouri', 'country': 'United States', 'facility': 'University of Missouri, Dept of Otorlaryngology', 'geoPoint': {'lat': 38.95171, 'lon': -92.33407}}, {'zip': '68505', 'city': 'Lincoln', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Asthma, Allergy, and Immunology Associates, PC', 'geoPoint': {'lat': 40.8, 'lon': -96.66696}}, {'zip': '07712', 'city': 'Ocean City', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Atlantic Research Center', 'geoPoint': {'lat': 39.27762, 'lon': -74.5746}}, {'zip': '11042', 'city': 'New Hyde Park', 'state': 'New York', 'country': 'United States', 'facility': 'ENT and Allergy Associates', 'geoPoint': {'lat': 40.7351, 'lon': -73.68791}}, {'zip': '10003', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Mount Sinai Downtown Union Square', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10016', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Madison ENT and Facial Plastic Surgery', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '28204', 'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Allergy Asthma & Immunology Relief of Charlotte', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '73120', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Allergy Asthma & Clinical Research Center', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '74136', 'city': 'Tulsa', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Vital Prospects Clinical Research Institute, P.C.', 'geoPoint': {'lat': 36.15398, 'lon': -95.99277}}, {'zip': '97202', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Northwest Research Center', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '18017', 'city': 'Bethlehem', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Specialty Physician Associates', 'geoPoint': {'lat': 40.62593, 'lon': -75.37046}}, {'zip': '19104', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Hospital at the University of PA', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '29425', 'city': 'Charleston', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Medical University of South Carolina', 'geoPoint': {'lat': 32.77632, 'lon': -79.93275}}, {'zip': '29420', 'city': 'North Charleston', 'state': 'South Carolina', 'country': 'United States', 'facility': 'National Allergy and Asthma Research', 'geoPoint': {'lat': 32.85462, 'lon': -79.97481}}, {'zip': '37660', 'city': 'Kingsport', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Holston Medical Group', 'geoPoint': {'lat': 36.54843, 'lon': -82.56182}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'University of TX Health Science Ctr at Houston', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'STAAMP Research, LLC', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '84102', 'city': 'Salt Lake City', 'state': 'Utah', 'country': 'United States', 'facility': 'Intermountain Ear, Nose & Throat', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'zip': '84790', 'city': 'St. George', 'state': 'Utah', 'country': 'United States', 'facility': 'Chrysallis Clinical Research', 'geoPoint': {'lat': 37.10415, 'lon': -113.58412}}, {'zip': '23507', 'city': 'Norfolk', 'state': 'Virginia', 'country': 'United States', 'facility': 'Eastern Virginia Medical School', 'geoPoint': {'lat': 36.84681, 'lon': -76.28522}}, {'zip': '98225', 'city': 'Bellingham', 'state': 'Washington', 'country': 'United States', 'facility': 'Bellingham Asthma, Allergy & Immunology Clinic', 'geoPoint': {'lat': 48.75955, 'lon': -122.48822}}, {'zip': '99201', 'city': 'Spokane Valley', 'state': 'Washington', 'country': 'United States', 'facility': 'Spokane ENT', 'geoPoint': {'lat': 47.67323, 'lon': -117.23937}}, {'zip': '4002', 'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'UMHAT - Kaspela EOOD', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'zip': '1000', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'MC Iskar', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1303', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Multiprofile Hospital for Active Treatment Serdika', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1606', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'MC Pirogov', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1606', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'The Military Medical Academy (MHAT)', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1606', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Мinistry of Interior - Medical Institute', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': 'V6Z 1Y6', 'city': 'Vancouver', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'University of British Columbia and Providence Health Care', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'zip': 'N6A 4V2', 'city': 'London', 'state': 'Ontario', 'country': 'Canada', 'facility': "St. Joseph's Healthcare London", 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'zip': 'G1S 4L8', 'city': 'Québec', 'country': 'Canada', 'facility': 'CHU de Quebec, pavillon Hopital Saint- Sacrement', 'geoPoint': {'lat': 46.81228, 'lon': -71.21454}}, {'zip': '0112', 'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'Ltd Acad. Fridon Todua Medical Center', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'zip': '0112', 'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'Ltd Israel-Georgian Medical Research Clinic - Helsicore', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'zip': '0114', 'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'JSC Curatio', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'zip': '0160', 'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'Ltd Aversi Clinic', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'zip': '0179', 'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'Ltd Simon Khechinashvili University Hospital', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'zip': '32-650', 'city': 'Kęty', 'state': 'Lesser Poland Voivodeship', 'country': 'Poland', 'facility': 'Jarosław Ślifirski Indywidualna Praktyka Lekarska', 'geoPoint': {'lat': 49.88214, 'lon': 19.22333}}, {'zip': '32-020', 'city': 'Wieliczka', 'state': 'Lesser Poland Voivodeship', 'country': 'Poland', 'facility': 'Centrum Medyczne Biotamed', 'geoPoint': {'lat': 49.98738, 'lon': 20.06473}}, {'zip': '50-224', 'city': 'Wroclaw', 'state': 'Lower Silesian Voivodeship', 'country': 'Poland', 'facility': 'Medicus Sp z o.o.', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '37-100', 'city': 'Łańcut', 'state': 'Podkarpackie Voivodeship', 'country': 'Poland', 'facility': 'Mini Clinic Paweł Białogłowski', 'geoPoint': {'lat': 50.06871, 'lon': 22.22912}}, {'zip': '40-611', 'city': 'Katowice', 'state': 'Silesian Voivodeship', 'country': 'Poland', 'facility': 'Centrum Medyczne Angelius Provita', 'geoPoint': {'lat': 50.2597, 'lon': 19.02173}}, {'zip': '42-600', 'city': 'Tarnowskie Góry', 'state': 'Silesian Voivodeship', 'country': 'Poland', 'facility': 'NZOZ Centrum Medyczne LiMED', 'geoPoint': {'lat': 50.44548, 'lon': 18.86147}}, {'zip': '60-537', 'city': 'Poznan', 'state': 'Wielkopolska', 'country': 'Poland', 'facility': 'NZOZ Imedica', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'zip': '15-181', 'city': 'Bialystok', 'country': 'Poland', 'facility': 'ReumaClinic', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'zip': '88-100', 'city': 'Inowrocław', 'country': 'Poland', 'facility': 'Przychodnia "Narutowicza"', 'geoPoint': {'lat': 52.79886, 'lon': 18.26387}}, {'zip': '30-033', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Centrum Medyczne All Med - Krakow', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '31-572', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Medical Center Woś i Piwowarczyk', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '20-552', 'city': 'Lublin', 'country': 'Poland', 'facility': 'Centrum Alergologii', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'zip': '47-100', 'city': 'Strzelce Opolskie', 'country': 'Poland', 'facility': 'Centrum Medyczne Lucyna Andrazej Dymek - Strzelce Opolskie', 'geoPoint': {'lat': 50.5107, 'lon': 18.30056}}, {'zip': '21-040', 'city': 'Świdnik', 'country': 'Poland', 'facility': 'NZOZ "Ignis" dr med. Alicja Łobińska', 'geoPoint': {'lat': 51.21898, 'lon': 22.69621}}, {'zip': '41-600', 'city': 'Świętochłowice', 'country': 'Poland', 'facility': 'NZOZ Przychodnia Medycyny Rodzinnej', 'geoPoint': {'lat': 50.29636, 'lon': 18.91726}}, {'zip': '119435', 'city': 'Moscow', 'state': 'Moskovskaya Obl.', 'country': 'Russia', 'facility': 'I.M. Sechenov First Moscow State Medical University-University Hospital No.1 - Ear, Nose, and Throat Clinic', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '129110', 'city': 'Moscow', 'state': 'Moskovskaya Obl.', 'country': 'Russia', 'facility': 'Moscow Regional Scientific Research Clinical Institute n.a. M.F. Vladimirsky (MONIKI)', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '197022', 'city': 'Saint Petersburg', 'state': 'Sankt-Peterburg', 'country': 'Russia', 'facility': 'Saint-Petersburg State Medical University n.a. I.P. Pavlov', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '214031', 'city': 'Smolensk', 'state': 'Smolenskaya Obl', 'country': 'Russia', 'facility': 'Smolensk, "Uromed"', 'geoPoint': {'lat': 54.77826, 'lon': 32.05088}}, {'zip': '150062', 'city': 'Yaroslavl', 'state': 'Yaroslavskaya Obl.', 'country': 'Russia', 'facility': 'Yaroslavl Regional Clinical Hospital', 'geoPoint': {'lat': 57.62987, 'lon': 39.87368}}, {'zip': '121359', 'city': 'Moscow', 'country': 'Russia', 'facility': 'Central Clinical Hospital with Polyclinic" Office of Affairs of the President of the Russian Federation', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '190013', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Saint-Petersburg Institute of Ear, Nose, Throat, and Speech (The RSFSR Ministry of Health)', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '222 41', 'city': 'Lund', 'state': 'Skåne County', 'country': 'Sweden', 'facility': 'ONH Klinikun Skane Universitetssjukhuset (Lund - Oron- Nas- Och Halskliniken)', 'geoPoint': {'lat': 55.70584, 'lon': 13.19321}}, {'zip': '171 76', 'city': 'Stockholm', 'state': 'Stockholm County', 'country': 'Sweden', 'facility': 'Karolinska University Hospital', 'geoPoint': {'lat': 59.32938, 'lon': 18.06871}}, {'zip': '25187', 'city': 'Helsingborg', 'state': 'Sverige', 'country': 'Sweden', 'facility': 'Helsingborg Hospital', 'geoPoint': {'lat': 56.04673, 'lon': 12.69437}}, {'zip': '413 45', 'city': 'Gothenburg', 'state': 'Vastra Gotaland Lan', 'country': 'Sweden', 'facility': 'ONH Kliniken Sahlgrenska Universitetsynkhiset', 'geoPoint': {'lat': 57.70716, 'lon': 11.96679}}, {'zip': '114 28', 'city': 'Stockholm', 'country': 'Sweden', 'facility': 'Sofiahemmet Hospital', 'geoPoint': {'lat': 59.32938, 'lon': 18.06871}}, {'city': 'Cardiff', 'state': 'CF14 4XW', 'country': 'United Kingdom', 'facility': 'University Hospital of Wales', 'geoPoint': {'lat': 51.48, 'lon': -3.18}}, {'zip': 'DL3 6HX', 'city': 'Darlington', 'country': 'United Kingdom', 'facility': 'Darlington Memorial Hospital', 'geoPoint': {'lat': 54.52429, 'lon': -1.55039}}, {'zip': 'SG1 4AB', 'city': 'Stevenage', 'country': 'United Kingdom', 'facility': 'Lister Hospital', 'geoPoint': {'lat': 51.90224, 'lon': -0.20256}}, {'zip': 'SK2 7JE', 'city': 'Stockport', 'country': 'United Kingdom', 'facility': 'Stockport NHS Foundation Trust (Stepping Hill Hospital Base)', 'geoPoint': {'lat': 53.40979, 'lon': -2.15761}}, {'zip': 'WN1 2NN', 'city': 'Wigan', 'country': 'United Kingdom', 'facility': 'Wrightington, Wigan and Leigh NHS Foundation Trust', 'geoPoint': {'lat': 53.54296, 'lon': -2.63706}}], 'overallOfficials': [{'name': 'Jennifer Carothers', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Optinose US Inc.'}, {'name': 'John Messina', 'role': 'STUDY_CHAIR', 'affiliation': 'Optinose US Inc.'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Optinose US Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}